NCT07059507Recruiting
Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.
Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The prevalence of incidental thyroid cancer (ITC) in Graves' Disease (GD) patients undergoing thyroidectomy appears higher than historically believed, potentially exceeding 10% in large contemporary series, although significant variability exists. The presence of nodules is a strong predictor, while the roles of age, sex, and BMI require clarification. Most ITCs are papillary thyroid microcarcinoma(PTMCs) with generally favorable prognoses, but concerns about aggressiveness persist. The purpose of the present study is to accurately evaluate the prevalence of incidental thyroid carcinoma (ITC), including microcarcinomas, in a prospectively enrolled cohort of patients undergoing total thyroidectomy for Graves' disease, utilizing standardized pathological examination protocols and secondary outcomes including predictors and histopathological characteristics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 280 (estimated)
- First submitted
- 1 Jul 2025
- Start date
- 15 Jul 2025
- Primary completion date
- 15 Dec 2026
- Lead sponsor
- Minia University
- Diseases
- Thyroid cancer
- NCT number
- NCT07059507
What you commit to
- Study type: Observational
- Planned participants: 280
- From 15 Jul 2025 to the primary completion date, 15 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous thyroid surgery.
- Previous neck irradiation.
Other illness
- Preoperative diagnosis of thyroid malignancy confirmed by fine-needle aspiration (FNA) cytology (Bethesda V or VI) , the focus is on incidental carcinoma.
- Inability to provide informed consent (e.g., due to cognitive impairment).
- Patients undergoing thyroidectomy primarily for reasons other than Graves' disease (e.g., primary indication is large non-toxic MNG).
Age
- Age less than 18 years.
Other
- Patients undergoing less than total thyroidectomy (e.g., lobectomy, subtotal thyroidectomy).
Who the study is looking for
- Age 18 years or older.
- Confirmed diagnosis of Graves' disease based on clinical features (e.g., diffuse goiter, ophthalmopathy if present) and biochemical evidence (suppressed TSH, elevated free T4 and/or T3) and/or positive TSH receptor antibody (TRAb) test.
- Indication for total thyroidectomy for Graves' disease, based on established guidelines:
- Relapse or persistence of hyperthyroidism after a course of antithyroid drugs (ATDs).
- Intolerance or adverse reaction to ATDs. Patient preference for surgery over radioactive iodine (RAI) or long-term ATDs. Presence of a large goiter causing compressive symptoms. Coexisting suspicious thyroid nodule(s) on preoperative evaluation. Moderate to severe active Graves' ophthalmopathy where RAI is relatively contraindicated.
- Patient is scheduled for total thyroidectomy (near-total or subtotal thyroidectomy patients will be excluded).
- Ability and willingness to provide written informed consent.
- Ability to understand study procedures and requirements.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Minia University Hospital Coordinator of this site? Confirm its status | Minya | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.